Paclitaxel liquid for platinum-resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new liquid form of paclitaxel (a common chemotherapy drug) in women whose ovarian, fallopian tube, or primary peritoneal cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this new formulation is safe and effective for this difficult-to-treat situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous (a specific subtype).
- Your cancer did not respond to platinum chemotherapy, or it came back within 6 months after your last platinum treatment.
- You have at least one tumor that can be measured on a scan (like CT or MRI).
- You are physically able to care for yourself (score 0 or 1 on a standard health scale).
- You have not already received paclitaxel (Taxol) for platinum-resistant disease.
- You have adequate bone marrow, kidney, and liver function, and a heart pumping function of at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
This trial tests whether adding losartan, a blood pressure medication, to the chemotherapy drug paclitaxel can help treat ovarian cancer that has returned after platinum-based treatment. The goal is to see if this combination can slow or stop the cancer's growth.
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This study tests giving a chemotherapy drug (paclitaxel) as a fine mist directly into the belly using a small camera tube. It is for ovarian cancer that has stopped responding to standard IV chemo, and aims to fight the cancer where it is while possibly causing fewer side effects.
Hear when a new Platinum-Resistant Primary Peritoneal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.